Ansuvimab

Ansuvimab is a human monoclonal antibody used for the treatment of acute rabies virus infection. It is specifically indicated for adults and children of all ages. Ansuvimab works by neutralizing the rabies virus, preventing it from infecting healthy cells in the body. The antibody binds to a specific protein on the surface of the rabies virus, blocking its ability to enter and replicate within cells.

Ansuvimab is administered as a single intravenous infusion. Its use is typically reserved for patients who have already developed clinical signs and symptoms of rabies infection. It is crucial to note that Ansuvimab is not a substitute for rabies post-exposure prophylaxis (PEP), which includes wound care, rabies immunoglobulin, and rabies vaccine. PEP should still be administered according to standard guidelines to individuals who have been exposed to a potentially rabid animal.

Ansuvimab represents a significant advancement in the treatment of rabies, offering a potentially life-saving therapy for a disease that is nearly always fatal once symptoms appear. Prior to the development of Ansuvimab, treatment options for rabies were largely supportive, with limited efficacy in reversing the disease's progression.

Common side effects associated with Ansuvimab administration may include infusion-related reactions such as fever, chills, nausea, and headache. As with any monoclonal antibody, there is also a potential risk of hypersensitivity reactions, including anaphylaxis. Patients should be closely monitored during and after the infusion for any signs or symptoms of an adverse reaction.

The development and approval of Ansuvimab have been driven by the critical need for effective therapies to combat the devastating effects of rabies infection. It is an important tool in the ongoing effort to reduce the global burden of this deadly disease.